Canada clears Boston Scientific Taxus Liberte stent

TriMed Staff | | Health Imaging | Screening

Boston Scientific has received approval to sell its Taxus Liberte paclitaxel-eluting coronary stent system in Canada.

The Natick, Mass.-based company said that Health Canada's Therapeutic Products Directorate, the authority that regulates pharmaceutical drugs and medical devices, has approved its use.

Boston Scientific said it plans to launch the product immediately in Canada.

The Taxus Liberte stent has previously been approved for sale in Europe and other international markets and is currently awaiting approval by the FDA and is, therefore, not available for sale in the United States. 

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.